CagriSema produces higher rates of nausea (55% versus 31%) and vomiting (26% versus 12%) compared to tirzepatide in their respective clinical trials
The medication also influences gut motility throughout the entire gastrointestinal tract, not just the stomach
The distinct mode of CTR and AMYR engagement by Cagri revealed in the current study, together with the correlated distinctions in functional responses at individual receptors, is likely to be important in the differentiated, high efficacy, of Cagri as a first-in-class obesity drug in both preclinical animal models and in treatment of obese patients in clinical trials 2,3,4
Expect 1015% on orforglipron, 1415% on injectable semaglutide, and 1820% on tirzepatide if you take the drug consistently at target dose with lifestyle support
Studies have established a clear correlation between low vitamin D levels and the severity of periodontal disease, with vitamin D deficiency contributing to inflammation and alveolar bone loss (75, 76)
